Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Diamedica Therapeutics ( (DMAC) ) just unveiled an update.
On May 15, 2025, DiaMedica Therapeutics Inc. held its Annual General Meeting of Shareholders, where 45.1% of the voting shares were represented. The meeting resulted in the election of seven directors, the appointment of Baker Tilly US, LLP as the independent registered public accounting firm, and the advisory approval of executive compensation.
The most recent analyst rating on (DMAC) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Diamedica Therapeutics stock, see the DMAC Stock Forecast page.
Spark’s Take on DMAC Stock
According to Spark, TipRanks’ AI Analyst, DMAC is a Neutral.
Diamedica Therapeutics faces significant financial hurdles with no revenue and rising net losses, leading to a low financial performance score. Technical analysis presents mixed signals, adding uncertainty. Despite this, the company’s optimistic guidance and significant progress in clinical trials offer some potential, reflected in a moderate earnings call score. However, the speculative nature of its valuation due to the absence of earnings and dividends remains a key risk.
To see Spark’s full report on DMAC stock, click here.
More about Diamedica Therapeutics
DiaMedica Therapeutics Inc. operates in the biopharmaceutical industry, focusing on the development of novel therapies for neurological and kidney diseases.
Average Trading Volume: 96,386
Technical Sentiment Signal: Sell
Current Market Cap: $170.6M
Learn more about DMAC stock on TipRanks’ Stock Analysis page.